MA42509A - Formes d'adipate et compositions d'inhibiteurs de biaryle de la tyrosine kinase de bruton - Google Patents
Formes d'adipate et compositions d'inhibiteurs de biaryle de la tyrosine kinase de brutonInfo
- Publication number
- MA42509A MA42509A MA042509A MA42509A MA42509A MA 42509 A MA42509 A MA 42509A MA 042509 A MA042509 A MA 042509A MA 42509 A MA42509 A MA 42509A MA 42509 A MA42509 A MA 42509A
- Authority
- MA
- Morocco
- Prior art keywords
- adipate
- compositions
- forms
- tyrosine kinase
- bruton tyrosine
- Prior art date
Links
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical group OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 title 1
- 150000005347 biaryls Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173896P | 2015-06-10 | 2015-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42509A true MA42509A (fr) | 2018-06-06 |
Family
ID=56134710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042509A MA42509A (fr) | 2015-06-10 | 2016-06-10 | Formes d'adipate et compositions d'inhibiteurs de biaryle de la tyrosine kinase de bruton |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20180179189A1 (fr) |
| EP (1) | EP3307731A1 (fr) |
| JP (1) | JP2018521029A (fr) |
| AU (1) | AU2016274961A1 (fr) |
| CA (1) | CA2988576A1 (fr) |
| MA (1) | MA42509A (fr) |
| WO (1) | WO2016201271A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10813612B2 (en) | 2019-01-25 | 2020-10-27 | Cleerly, Inc. | Systems and method of characterizing high risk plaques |
| CN110627775B (zh) * | 2019-10-24 | 2026-01-30 | 特科罗生物科技(成都)有限公司 | 一种小分子化合物 |
| CA3162872A1 (fr) | 2020-01-07 | 2021-07-15 | James K. MIN | Systemes, procedes et dispositifs d'analyse d'images medicales, de diagnostic, de stratification de risque, de prise de decision et/ou de suivi de maladie |
| US20220392065A1 (en) | 2020-01-07 | 2022-12-08 | Cleerly, Inc. | Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking |
| US11969280B2 (en) | 2020-01-07 | 2024-04-30 | Cleerly, Inc. | Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking |
| AU2022362107A1 (en) | 2021-10-11 | 2024-05-02 | Anebulo Pharmaceuticals, Inc. | Crystalline forms of a cannabinoid receptor type 1 (cb1) modulator and methods of use and preparation thereof |
| US12406365B2 (en) | 2022-03-10 | 2025-09-02 | Cleerly, Inc. | Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination |
| US20250217981A1 (en) | 2022-03-10 | 2025-07-03 | Cleerly, Inc. | Systems, methods, and devices for image-based plaque analysis and risk determination |
| US20250143657A1 (en) | 2022-03-10 | 2025-05-08 | Cleerly, Inc. | Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination |
| US12440180B2 (en) | 2022-03-10 | 2025-10-14 | Cleerly, Inc. | Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201604595VA (en) * | 2013-12-11 | 2016-07-28 | Biogen Ma Inc | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
-
2016
- 2016-06-10 WO PCT/US2016/036952 patent/WO2016201271A1/fr not_active Ceased
- 2016-06-10 EP EP16730221.5A patent/EP3307731A1/fr not_active Withdrawn
- 2016-06-10 US US15/580,561 patent/US20180179189A1/en not_active Abandoned
- 2016-06-10 CA CA2988576A patent/CA2988576A1/fr not_active Abandoned
- 2016-06-10 AU AU2016274961A patent/AU2016274961A1/en not_active Abandoned
- 2016-06-10 MA MA042509A patent/MA42509A/fr unknown
- 2016-06-10 JP JP2017564031A patent/JP2018521029A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20180179189A1 (en) | 2018-06-28 |
| EP3307731A1 (fr) | 2018-04-18 |
| JP2018521029A (ja) | 2018-08-02 |
| CA2988576A1 (fr) | 2016-12-15 |
| AU2016274961A1 (en) | 2018-01-04 |
| WO2016201271A1 (fr) | 2016-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42509A (fr) | Formes d'adipate et compositions d'inhibiteurs de biaryle de la tyrosine kinase de bruton | |
| DK3265084T3 (da) | Farmaceutiske formuleringer af Bruton's tyrosinkinase-hæmmer | |
| MA42510A (fr) | Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton | |
| EP3414234A4 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| EP3310776A4 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| EP3360078A4 (fr) | Caractérisation de systèmes physiques dynamiques | |
| EP3405192A4 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| IL257203B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
| MA42242A (fr) | Inhibiteurs de la tyrosine kinase | |
| EP3317273A4 (fr) | Inhibiteurs d'egfr et méthodes d'utilisation de ceux-ci | |
| MA41350A (fr) | Synthèse d'un inhibiteur de la tyrosine kinase de bruton | |
| HUE055458T2 (hu) | Kompozíciók és módszerek 5'-Cap RNS-ek szintézisére | |
| MA41252A (fr) | Formes solides d'un inhibiteur d'ask 1 | |
| DK3303334T3 (da) | Tyrosinkinasehæmmere | |
| MA41827A (fr) | Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton | |
| MA41828A (fr) | Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton | |
| ZA201903694B (en) | Inhibitors of bruton's tyrosine kinase | |
| MA45656A (fr) | Nouveaux pyrimidine carboxamides utilisées comme inhibiteurs de l'enzyme vanin-1 | |
| IL259862B (en) | Inhibitors of proton tyrosine kinase and methods of using them | |
| ZA201906887B (en) | Bruton's tyrosine kinase inhibitors | |
| EP3543239A4 (fr) | Inhibiteur sélectif de la tyrosine kinase de bruton et son utilisation | |
| MA52629A (fr) | Agents inhibiteurs de la tyrosine kinase de bruton | |
| MA42546A (fr) | Combinaisons d'inhibiteur de la tyrosine kinase de bruton et leurs utilisations | |
| IL264341A (en) | Succinate forms and preparations of proton tyrosine kinase inhibitors | |
| EP3415524A4 (fr) | INHIBITEUR D'EXPRESSION DE L'a-SYNUCLÉINE |